Efficacy and safety of adjunctive bitopertin (10 and 20mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics - Results from the Phase III FlashLyte Study

Schizophrenia Research

Volumn 158, Issue 1-3, 2014, Pages

  Blaettler, Thomas ^a   Bugarski Kirola, Dragana ^a   Fleischhacker, W Wolfgang ^b   Bressan, Rodrigo ^c   Arango, Celso ^d   Abi Saab, Danielle ^a   Napieralski, Julie ^a   Dixon, Mark ^a   Marder, Stephen ^e  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BITOPERTIN; COMPLEMENT FACTOR H; HEMOGLOBIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PLACEBO;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); NEGATIVE SYNDROME; OUTCOME ASSESSMENT; PERSONAL AND SOCIAL PERFORMANCE SCORE; PHASE 3 CLINICAL TRIAL (TOPIC); POSITIVE AND NEGATIVE SYNDROME SCALE; POSTSYNAPTIC POTENTIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 84906815790     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.07.036     Document Type: Article

References (0)